Abstract
Aim
By taking the example of rotavirus in Europe, the aim of this article is to review the role of scientific societies in the decision-making process to recommend new vaccines.
Subjects and methods
The guidelines for rotavirus vaccination issued by the European Society for Paediatric Diseases (ESPID) and the European Society for Paediatric Gastroenterology, Hepatitis and Nutrition (ESPGHAN) Expert Group are examined in the light of the methodology used and recommendations previously issued in the US.
Results
The experience of the ESPID-ESPGHAN Expert Group was largely positive. The group was supported equally by the two vaccine manufacturers involved in rotavirus vaccine production (Sanofi Pasteur MSD, Glaxo SmithKline). However, while benefiting from the input of manufacturers, the expert group developed its recommendations independently both from the industry and regulatory authorities in Europe.
Conclusion
With a new vaccine, there is always a lack of expertise at the country level. Gaps in knowledge can be overcome by information and discussion in order to increase awareness of disease and available interventions. The ESPID-ESPGHAN Expert Group recommendations for rotavirus vaccine in Europe constitute the first evidence-based attempt of its kind.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
I (Vesikari) selected the members of the original expert group. Representatives from ESPID and ESPGHAN were subsequently selected by the respective societies.
References
Advisory Committee on Immunisation Practices (ACIP) (2006) Prevention of rotavirus gastroenteritis in infants and children. Recommendations of the Advisory Committee on Immunisation Practices. MMWR 55:1–13
American Academy of Pediatrics (AAP) Committee on Infectious Diseases (2007) Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine. Pediatria 119:171–182
Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, GRADE Working Group (2004) Grading quality of evidence and strength of recommendation. BMJ 328:1490–1498
CDC (1999) Intussusception among recipients of rotavirus vaccine-United States, 1998–1999. MMRW 48:577–581
Joensuu J, Koskenniemi E, Pang X-L, Vesikari T (1997) Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350:1205–1209
Pediatric ROTavirus European CommitTee (PROTECT) (2006) The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 134:908–916
Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M, Human Rotavirus Vaccine Study Group.Instituto Nacional de Ciencas (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354:11–22
Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ (2005) More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 192(Suppl 1):S36–43
Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T (2006) Burden of rotavirus disease in European Union countries. Pediatr Inf Dis J 25(Suppl):S7–S11
Vesikari T, Isolauri E, D'Hondt E, Delem A, André FE, Zissis G (1984) Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1:977–981
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM, Rotavirus Efficacy and Safety Trial (REST) Study Team (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23–33
Vesikari T, van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V (in press) ESPID/ESPGHAN evidence-based recommendation for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr Suppl.
Conflict of interest statement
The author has received honoraria for lectures and has sat on advisory boards of both GSK and SPMSD.
Author information
Authors and Affiliations
Corresponding author
Additional information
The role of scientific societies in the decision-making process to recommend new vaccines: the example of rotavirus in Europe
Rights and permissions
About this article
Cite this article
Vesikari, T. The role of scientific societies in the decision-making process to recommend new vaccines: the example of rotavirus in Europe. J Public Health 16, 287–290 (2008). https://doi.org/10.1007/s10389-008-0205-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10389-008-0205-x